Novavax R&D chief Gregory Glenn (Novavax)
After Moderna and Pfizer's stellar results, the comeback players at Novavax face big questions about their best-in-class hunt in a frenzied Covid-19 vaccine race
On Nov. 9, Novavax R&D chief Gregory Glenn was awakened on his family farm to a news alert: Pfizer and BioNTech’s vaccine was more than 90% effective at preventing Covid-19.
It was incredible news for the world, and Glenn texted congratulations to old friends on the Pfizer-BioNTech team. But he also knew that it was complicated news for Novavax.
“I was not surprised that it worked, but to have 90, 95% efficacy? That’s really great,” Glenn told Endpoints News. “Admittedly, it puts a little additional pressure on me in other areas.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
